Revolutionizing diabetes care with only 41 patients
Context:
New type I diabetes treatment, IMCY-0098, a proinsulin-derived Imotope™ in Phase I developed by Imcyse with first results in only 41 patients
Impact:
– Biomarkers selected by KEM® were implemented in phase II with positive results.
– Positive Phase 1b data triggered Series B Pre-IPO funding of $40m
KEM®’s unique abilities in the unbiased analysis of small datasets with explainable AI enabled Ariana to deliver actionable and powerful insights on IMCY-0098 therapy.
Objectives:
– Identify biomarkers that could effectively select patients with the highest probability of benefiting from IMCY-0098 therapy.
– Identify surrogate biomarkers capable of capturing more efficiently the therapeutic impact of the treatment.
Method:
KEM® systematically associated the treatment and baseline characteristics with the efficacy of the treatment (insulin consumption, autoantibodies levels, MMT (Mixed Tolerance test) test, glycaemia). 32,079 relations were extracted and filtered on the statistical significance. KEM® enabled the systematic exploration of all connections between treatment and markers.
Results:
KEM® identified haplotype HLA DR4 as the most responsive subgroup. And CD4/GRB+(CD4, granzyme B+ T-cell) was associated with the dose and identified as a surrogate endpoint.